Herantis Pharma Oyj

HRPMF · OTC
Analyze with AI
12/31/2024
6/30/2024
12/31/2023
6/30/2023
Operating Activities
Net Income-$2,253-$2,687$2,075-$1,795
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$0
Change in WC-$1,257-$308-$248$357
Other Non-Cash$0-$40-$3,287-$279
Operating Cash Flow-$3,510-$3,035-$1,460-$859
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$607
Inv. Purchases$0-$1,500$0$0
Inv. Sales/Matur.-$0$1,026$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$0-$474$0$607
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$4,506$1
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$2,156-$5-$11-$1
Financing Cash Flow$2,156-$5$4,495$1
Forex Effect$0$0$0$0
Net Chg. in Cash$0-$3,512$0$3,926
Supplemental Information
Beg. Cash$1,989$5,501$3,926$0
End Cash$635$1,989$5,503$3,926
Free Cash Flow-$3,510-$3,035-$1,460-$859